Postmarketing Surveillance Study (as Per § 67 (6) AMG [German Drug Law]) of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease

NCT02231424 COMPLETED

The aim of this postmarketing surveillance is to obtain further information about the tolerability and efficacy of Berodual® metered-dose inhaler in the treatment of chronic obstructive respiratory tract disease under conditions of daily practice

Details

Lead sponsor	Boehringer Ingelheim
Status	COMPLETED
Enrolment	713
Start date	1999-01

Conditions

• Pulmonary Disease, Chronic Obstructive

Interventions

• Drug: Berodual®

Primary outcomes

• Overall severity of the clinical picture rated on a 4-point scale — after 3 and 6 weeks